COX-2 inhibitors celecoxib and rofecoxib prevent oxidative DNA fragmentation

Anticancer Research

Volumn 26, Issue 3 A, 2006, Pages 2003-2007

  Matthias, Christoph ^a   Schuster, Marie Therese ^a   Zieger, Sabina ^a   Harreus, Ulrich ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antimutagenic effect; Chemoprevention; Comet assay; Cyclooxygenase inhibitor; DNA repair

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DNA FRAGMENT; ROFECOXIB;

ARTICLE; CLINICAL ARTICLE; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; DRUG INHIBITION; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; PHARYNX; PRIORITY JOURNAL;

COMET ASSAY; CYCLOOXYGENASE 2 INHIBITORS; DNA DAMAGE; HEAD AND NECK NEOPLASMS; HUMANS; HYDROGEN PEROXIDE; LACTONES; LARYNGITIS; LEUKOPLAKIA; MOUTH MUCOSA; OXIDATIVE STRESS; PHARYNX; PRECANCEROUS CONDITIONS; PYRAZOLES; SULFONAMIDES; SULFONES;

EID: 33745617697     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Mohan S and Epstein JB: Carcinogenesis and cyclooxygenase: the potential role of COX-2 inhibition in upper aerodigestive tract cancer. Oral Oncol 39: 537-546, 2003.
2. Smith WL, DeWitt DL and Garavito RM: Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69: 145-182, 2000.
3. Wiese FW, Thompson, PA and Kadlubar FF: Carcinogen substrate specifity of human COX-1 and COX-2. Carcinogenesis 14: 1279-1283, 1993.
4. Renkonen J, Wolff H and Paavonen T: Expression of cyclooxygenase-2 in human tongue carcinoma and its precursor lesions. Virchows Arch 440: 594-597, 2002.
5. Chan G, Boyle JO, Yang EK et al: Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 59: 991-994, 1999.
6. Williams CS, Tsujii M, Reese J et al: Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 105: 1589-1594, 2000.
7. Goodwin JS and Ceuppens JL: Regulation of immune response by prostaglandins. J Clin Immunol 3: 295-315, 1983.
8. Gallo O, Franchi A, Magnelli L et al: Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 3: 53-61, 2001.
9. Tsujii M and DuBois RN: Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83: 493-501, 1995.
10. Stolina M, Sharma S and Lin Y: Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 164: 361-370, 2000.
11. Sheng H, Shao J, Morrow JD et al: Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 58: 362-366, 1998.
12. Jones MK, Wang H, Peskar BM et al: Inhibition of angiogenesis by nonsteroidal antiinflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 5: 1418-1423, 1999.
13. Chruch RD, Fleshman JW and McLeod HL: Cyclooxygenase 2 inhibition in colorectal cancer therapy. Br J Surg 90: 1055-1067, 2003.
14. Eling TE, Thompson DC, Foureman GL et al: Prostaglandin H synthase and xenobiotic oxidation. Annu Rev Pharmacol Toxicol 30: 1-45, 1990.
15. Shiotani H, Denda A, Yamamoto K et al: Increased expression of cyclooxygenase-2 protein in 4-nitroquinoline-1-oxide induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide. Cancer Res 61: 1451-1456, 2001.
16. Nishimura G, Yanoma S, Satake K et al: An experimental model of tumor dormancy therapy for advanced head and neck carcinoma. Jpn J Cancer Res 91: 1199-1203, 2000.
17. Singh NP, Danner DB, Tice RR et al: DNA damage and repair with age in individual human lymphocytes. Mutat Res 237: 123-130, 1990.
18. Olive PL and Banáth JP: Sizing highly fragmented DNA in individual apoptotic cells using the Comet assay and a DNA crosslinking agent. Exp Cell Res 221: 19-26, 1995.
19. Tice R, Agurell E, Anderson D et al: Single cell gel/Comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 35: 206-221, 2000.
20. Bennett A, Carter RL, Stamford IF et al: Prostaglandin-like material extracted from squamous cell carcinomas of the head and neck. Br J Cancer 41: 204-208, 1980.
21. Jung TTK, Berlinger NT and Juhn SK: Prostaglandins in squamous cell carcinoma of the head and neck: a preliminary study. Laryngoscope 95: 307-312, 1985.
22. DuBois RN, Awad J, Morrow et al: Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-alpha and phorbol ester. J Clin Invest 93: 493-498, 1994.
23. Mestre JR, Subbaramaiah K, Sacs PG et al: Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous cell carcinoma cells. Cancer Res 57: 2890-2895, 1997.
24. Boyle JO, Hakim J, Koch W et al: The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 55: 4477-4480, 1993.
25. Thun MJ, Namboodiri MM, Heath CW Jr et al: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325: 1593-1596, 1991.
26. Schreinemachers DM and Everson RB: Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5: 138-146, 1994.
27. Funkhouser EM and Sharp GB: Aspirin and reduced risk of esophageal carcinoma. Cancer 76: 1116-1119, 1995.
28. Bardou M, Barkun AN, Ghosn J et al: Effect of chronic intake of NSAIDs and cyclooxygenase-2-selective inhibitors on esophageal cancer incidence. Clin Gastroenterol Hepatol 2(10): 880-887, 2004.
29. Perkins TM and Shklar G: Delay in hamster buccal bouch carcinogenesis by aspirin and indomethacin. Oral Surg Oral Med Oral Pathol 55: 170-178, 1982.
30. Sumitani K, Kamijo R, Toyoshima T et al: Specific inhibition of cyclooxygenase-2 results in inhibition of proliferation of oral cancer cell lines via suppression of prostaglandin E2 production. J Oral Pathol Med 30: 41-47, 2001.
31. Kelley DJ, Mestre JR, Subbaramaiah K et al: Benzo(a)pyrene upregulates cyclooxygenase-2 gene expression in oral epithelial cells. Carcinogenesis 18: 795-799, 1997.
32. Krotz F, Schiele TM, Klauss V et al: Selective Cox-2 inhibitors and risk of myocardial infarction. J Vasc Res 42(4): 312-324, 2005.
33. Jones SC: Relative thromboembolic risks associated with COX-2 inhibitors. Ann Pharmacother 59(7): 1249-1259, 2005.